Leucine is one of the three branched-chain amino acids (BCAAs) and is unique among them in that it is the primary nutritional signal that activates the mechanistic target of rapamycin (mTOR) pathway — the intracellular signalling pathway that regulates cell growth, cell proliferation, protein synthesis, and autophagy. Leucine is the most potent of all the amino acids at activating mTOR — it acts as a nutrient sensor that indicates the availability of amino acids for protein synthesis, and when leucine is abundant, mTOR is activated and protein synthesis is promoted. When leucine is low (as during fasting or during weight loss diets), mTOR is inhibited, protein synthesis is reduced, and autophagy (the degradation and recycling of cellular proteins and organelles) is activated. This leucine-mTOR system is one of the most important regulatory mechanisms in cellular metabolism, and its dysregulation is implicated in some of the most common conditions of modern civilisation, including sarcopenia (age-related muscle loss), cachexia (muscle wasting in chronic disease), obesity, and the metabolic dysfunction that characterises type 2 diabetes.
The mTOR Pathway
mTOR is a serine/threonine kinase that exists in two distinct complexes — mTORC1 and mTORC2. mTORC1 is the primary regulator of cell growth and protein synthesis, and it is the complex that is activated by leucine (and by other amino acids, by insulin, and by growth factors). When mTORC1 is activated, it phosphorylates two key downstream targets — 4E-BP1 (which when phosphorylated releases the translation initiation factor eIF4E and promotes cap-dependent translation) and S6K1 (which when phosphorylated promotes the translation of the 5 terminal oligopyrimidine tract (5 TOP) mRNAs that encode the ribosomal proteins and other components of the translation machinery). The net effect of mTORC1 activation is a marked increase in the rate of protein synthesis and in the capacity for cell growth. mTORC2 is primarily involved in the regulation of cell survival, cytoskeletal organisation, and the insulin signalling pathway.
The clinical importance of the leucine-mTOR pathway is most clearly seen in the conditions that are characterised by impaired muscle protein synthesis — including sarcopenia (age-related muscle loss), where the decline in anabolic hormones and the increase in anabolic resistance lead to a reduced response of muscle protein synthesis to leucine and to other anabolic stimuli; cachexia (muscle wasting in cancer, COPD, heart failure, and other chronic diseases), where the systemic inflammation produces a catabolic state in which muscle protein degradation exceeds muscle protein synthesis; and bed rest and immobilisation, where the absence of mechanical loading leads to a rapid and dramatic loss of muscle mass and strength. In all of these conditions, the provision of adequate leucine (as a supplement, as part of a BCAA preparation, or as part of a complete protein supplement) has been shown to improve the rate of muscle protein synthesis and to partially offset the muscle loss that characterises these conditions.
Leucine Threshold and Muscle Protein Synthesis
The muscle protein synthesis response to leucine has a characteristic threshold pattern — at low leucine doses (below approximately 2.5g), there is little or no increase in muscle protein synthesis; at moderate leucine doses (2.5-4g), there is a submaximal increase in muscle protein synthesis; and at higher leucine doses (above 4g), there is a maximal increase in muscle protein synthesis that is comparable to the response to a complete meal containing 25-30g of protein. This leucine threshold pattern is the scientific basis for the recommendation to consume approximately 2.5-4g of leucine per meal (from whey protein, dairy, meat, or soy) to maximally stimulate muscle protein synthesis. For older adults with sarcopenia, who have an elevated leucine threshold (they require more leucine to produce the same muscle protein synthesis response as younger adults), the evidence-based recommendation is to consume 4-5g of leucine per meal (or 40-45g of a high-quality leucine-rich protein source) to overcome the anabolic resistance that characterises sarcopenia.
Practical Application
For general leucine supplementation (as a muscle protein synthesis support strategy), the evidence-based dose is 3-5g of leucine daily, taken in divided doses before, during, or after exercise, or as part of a complete BCAA supplement. Leucine is the most evidence-based of all the amino acids for muscle protein synthesis support and is appropriate for athletes, for older adults with sarcopenia, and for people who are recovering from illness or surgery (when muscle mass is at risk). For comprehensive muscle support, leucine pairs well with the other BCAAs (isoleucine and valine, which together constitute the complete BCAA complex), with vitamin D (which has independent anabolic effects on muscle and which is often deficient in older adults), with creatine (which supports the ATP regeneration that is required for the muscle protein synthesis process), with resistance exercise (which provides the mechanical signal that synergises with the leucine signal to activate muscle protein synthesis), and with adequate protein intake (1.2-1.6g protein/kg body weight daily, from varied sources including whey, dairy, meat, fish, eggs, and plant proteins).
Leave a Reply